Filing Flows › Comparisons › SCL vs XAGE
Stepan vs Longevity Health Holdings: SCL and XAGE compared
Stepan is the larger company: $692M of revenue in its latest quarter (Q3 2026) against $396K for Longevity Health Holdings (Q2 2026). Stepan is growing faster (+17% against -21% a year earlier). Stepan is more profitable, with an operating margin of 3.8% against -182.9%.
Where the money goes: SCL and XAGE
Stepan (SCL) · Q3 2026
Stepan, Q3 2026: revenue $692M (+17% year over year), operating margin 3.8%, net earnings $17.8M, operating cash flow $29.3M. The chart follows the revenue to costs, profit and cash.
Longevity Health Holdings (XAGE) · Q2 2026
Longevity Health Holdings, Q2 2026: revenue $396K (-21% year over year), operating margin -182.9%, net loss $1.9M, operating cash flow −$224K. The chart follows the revenue to costs, profit and cash.
| Stepan (SCL) | Longevity Health Holdings (XAGE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $692M | $396K |
| Revenue growth, Y/Y | +17% | -21% |
| Gross margin | 12.7% | — |
| Operating margin | 3.8% | -182.9% |
| Net earnings | $17.8M | −$1.9M |
| Net margin | 2.6% | -475.6% |
| Operating cash flow | $29.3M | −$224K |
| Free cash flow | $8.2M | — |
| Market value | $1.5B | — |
| Analysts’ mean target | $85.00 | — |
Where the revenue comes from
Stepan
- Surfactants: $487M (70%)
- Polymers: $179M (26%)
- Specialty Products: $26.9M (4%)
Questions
Which is bigger, Stepan or Longevity Health Holdings?
Stepan is the larger company: $692M of revenue in its latest quarter (Q3 2026) against $396K for Longevity Health Holdings (Q2 2026).
Is Stepan or Longevity Health Holdings growing faster?
Stepan is growing faster (+17% against -21% a year earlier).
Which is more profitable, Stepan or Longevity Health Holdings?
Stepan is more profitable, with an operating margin of 3.8% against -182.9%.
More: Stepan earnings · how Stepan makes money · Longevity Health Holdings earnings · how Longevity Health Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.